OpenVSafe by OpenVAERS
Search V-safe

76X-93161-85438

2 vaccinations 5 coded responses 10 check-ins 5 free-text entries 0 call cases
Sex
—
Age at first dose
41-45
ZIP prefix
021 / MA
Registered
2021-01-25
Relationship
Self
Race
White
Ethnicity
Not Hispanic or Latino

Timeline

  1. 2021-01-04
    Dose 1 — Pfizer-BioNTech
  2. 2021-01-22
    Dose 2 — Pfizer-BioNTech
  3. 2021-01-25
    Registered in v-safe
  4. 2021-01-25
    Survey response — days 1–6 daily, dose 2
    MedDRA: Lymphadenopathy — Feeling: Fair · Site: Pain, Redness · Headache, Fatigue or tiredness · Be unable to do your normal daily activities
    Free text: About 36 hours after 2nd injection I developed very significant 10x7cm area of axillary swelling/adenopathy that was and is quite tender accompanied by parenthesis mostly in ulnar and medial cutaneous distribution
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  5. 2021-01-26
    Survey response — days 1–6 daily, dose 2
    MedDRA: Lymphadenopathy — Feeling: Good · Site: Pain · Be unable to do your normal daily activities
    Free text: Continued significant ipsilateral axillary swelling/lymphadenopathy
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  6. 2021-01-27
    Survey response — days 1–6 daily, dose 2
    MedDRA: Lymphadenopathy — Feeling: Good · Headache
    Free text: Continued significant ipsilateral axillary adenopathy though not worse
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  7. 2021-01-28
    Survey response — days 1–6 daily, dose 2
    MedDRA: Lymphadenopathy — Feeling: Good · Fatigue or tiredness
    Free text: Continued ipsilateral axillary adenopathy though seems stable/not progressive and no more parestgesias
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  8. 2021-01-29
    Survey response — day 7, dose 2
    MedDRA: Lymphadenopathy — Feeling: Good
    Free text: Continued ipsilateral axillary adenopathy though seems to be decreasing
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  9. 2021-02-05
    Health check-in — day 14, dose 2
    Feeling: Good
    Adult check-in
  10. 2021-02-14
    Health check-in — day 21, dose 2
    Feeling: Good
    Adult check-in
  11. 2021-02-21
    Health check-in — day 28, dose 2
    Feeling: Good
    Adult check-in
  12. 2021-03-05
    Health check-in — day 42, dose 2
    Feeling: Good
    Adult check-in
  13. 2021-04-24
    Health check-in — 3 months, dose 2
    Feeling: Good
    Adult check-in

Vaccinations

DoseDateManufacturerCo-administered
12021-01-04Pfizer-BioNTech
22021-01-22Pfizer-BioNTech

Free text

Release 2 — days 1–6 daily, dose 2

2021-01-25

Systemic reaction (other): About 36 hours after 2nd injection I developed very significant 10x7cm area of axillary swelling/adenopathy that was and is quite tender accompanied by parenthesis mostly in ulnar and medial cutaneous distribution

2021-01-26

Systemic reaction (other): Continued significant ipsilateral axillary swelling/lymphadenopathy

2021-01-27

Systemic reaction (other): Continued significant ipsilateral axillary adenopathy though not worse

2021-01-28

Systemic reaction (other): Continued ipsilateral axillary adenopathy though seems stable/not progressive and no more parestgesias

Release 3 — day 7, dose 2

2021-01-29

Systemic reaction (other): Continued ipsilateral axillary adenopathy though seems to be decreasing

Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".

MedDRA terms by release

FieldPreferred term2021-092023-042024-11
SROLymphadenopathy ✓ ✓ ✓

✓ active code · ○ coded but marked inactive · blank = not in that release